Alnylam Pharmaceuticals, Inc. $ALNY Shares Purchased by Banco Bilbao Vizcaya Argentaria S.A.

Key Points

• Banco Bilbao Vizcaya Argentaria S.A. has increased its stake in Alnylam Pharmaceuticals by 2.7% during the 1st quarter, owning 22,763 shares valued at $6,146,000.
• Alnylam Pharmaceuticals reported $0.32 earnings per share (EPS) for the last quarter, surpassing analysts' expectations by $0.86 and showing a 17.3% year-over-year revenue growth.
• Insider selling includes significant transactions from executives, with EVP Pushkal Garg and Director Michael W. Bonney selling a combined total of over $6 million in shares recently.

Banco Bilbao Vizcaya Argentaria S.A. boosted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 2.7% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 22,763 shares of the biopharmaceutical company's stock after acquiring an additional 609 shares during the quarter. Banco Bilbao Vizcaya Argentaria S.A.'s holdings in Alnylam Pharmaceuticals were worth $6,146,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC acquired a new position in shares of Alnylam Pharmaceuticals during the 4th quarter valued at $243,000. Townsquare Capital LLC acquired a new position in shares of Alnylam Pharmaceuticals during the 4th quarter valued at $227,000. NewEdge Advisors LLC increased its position in shares of Alnylam Pharmaceuticals by 97,200.0% during the 4th quarter. NewEdge Advisors LLC now owns 973 shares of the biopharmaceutical company's stock valued at $229,000 after purchasing an additional 972 shares during the period. Dimensional Fund Advisors LP increased its position in shares of Alnylam Pharmaceuticals by 10.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 333,661 shares of the biopharmaceutical company's stock valued at $78,520,000 after purchasing an additional 32,272 shares during the period. Finally, Ossiam increased its position in shares of Alnylam Pharmaceuticals by 44.9% during the 4th quarter. Ossiam now owns 2,427 shares of the biopharmaceutical company's stock valued at $571,000 after purchasing an additional 752 shares during the period. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, EVP Pushkal Garg sold 1,455 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $458.41, for a total transaction of $666,986.55. Following the completion of the sale, the executive vice president owned 20,221 shares of the company's stock, valued at approximately $9,269,508.61. This trade represents a 6.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Michael W. Bonney sold 11,250 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, August 18th. The shares were sold at an average price of $450.00, for a total value of $5,062,500.00. Following the sale, the director directly owned 16,804 shares of the company's stock, valued at approximately $7,561,800. The trade was a 40.10% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 108,531 shares of company stock valued at $41,087,238. 1.50% of the stock is currently owned by company insiders.

Alnylam Pharmaceuticals Price Performance

ALNY opened at $458.31 on Thursday. The stock has a market cap of $60.08 billion, a price-to-earnings ratio of -185.55 and a beta of 0.25. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $466.31. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10. The stock has a fifty day moving average price of $354.46 and a 200 day moving average price of $294.11.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.54) by $0.86. The firm had revenue of $773,689 billion during the quarter, compared to analysts' expectations of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The business's revenue for the quarter was up 17.3% on a year-over-year basis. During the same quarter last year, the firm earned ($0.13) earnings per share. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Morgan Stanley lifted their price target on Alnylam Pharmaceuticals from $312.00 to $405.00 and gave the company an "equal weight" rating in a research report on Friday, August 1st. Chardan Capital lifted their target price on Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the stock a "buy" rating in a report on Friday, August 1st. Scotiabank lifted their target price on Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the stock a "sector outperform" rating in a report on Friday, August 1st. Truist Financial started coverage on Alnylam Pharmaceuticals in a report on Monday, July 21st. They issued a "buy" rating and a $385.00 target price on the stock. Finally, Canaccord Genuity Group raised their target price on Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. Twenty-two equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat, Alnylam Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $405.33.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.